APX3330 treatment on pancreatic cancer-associated endothelial cells (PCECs) demonstrated inhibition of tumor angiogenesis, further supporting the notion that APE1/Ref-1 redox activity may be a therapeutic target for many cancers [79]. The gene discussed is APEX1; the disease is familial pancreatic carcinoma.